Aurora Investment Managers LLC. Makes New Investment in IDEXX Laboratories, Inc. $IDXX

Key Points

• Aurora Investment Managers acquired 4,638 IDEXX Laboratories shares worth approximately $2.44 million, making IDXX about 1.5% of its portfolio. Institutional investors collectively own 87.84% of the company.
• Analyst sentiment remains positive, with six Buy ratings and four Holds, resulting in a consensus “Moderate Buy” rating and an average price target of $756. Citigroup and UBS both raised their targets to $670 while maintaining neutral ratings.
• IDEXX reported quarterly earnings of $4.27 per share, beating estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. Shares opened at $586.67, compared with a 52-week range of $518.55 to $769.98.

Aurora Investment Managers LLC. bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,638 shares of the company's stock, valued at approximately $2,442,000. IDEXX Laboratories comprises approximately 1.5% of Aurora Investment Managers LLC.'s investment portfolio, making the stock its 21st largest position.

A number of other large investors also recently made changes to their positions in IDXX. SHP Wealth Management bought a new stake in IDEXX Laboratories during the fourth quarter worth $26,000. Elevation Wealth Partners LLC increased its position in shares of IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock valued at $26,000 after purchasing an additional 32 shares during the last quarter. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $26,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $30,000. Finally, Arlington Trust Co LLC raised its stake in shares of IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company's stock worth $32,000 after purchasing an additional 19 shares during the period. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

IDXX has been the subject of several research reports. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Citigroup lifted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday. Weiss Ratings upgraded shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research note on Wednesday, July 29th. Finally, UBS Group increased their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $756.00.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $586.67 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a fifty-two week low of $518.55 and a fifty-two week high of $769.98. The firm has a market cap of $46.22 billion, a PE ratio of 41.26, a price-to-earnings-growth ratio of 3.20 and a beta of 1.54. The business has a 50 day moving average price of $559.73 and a 200-day moving average price of $585.79.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the business posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 14.82 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source